Sign in
CompletedNo phase

Gastric Emptying Recovery After GLP-1 RA Cessation

Key facts

Who runs it
Wonkwang University Hospital
Where
South Korea2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
186 people enrolled
Started
20 Nov 2025
Ended
12 Jan 2026
Type of study
Observational, 3 groups
Treatments tested
  • Preoperative gastric ultrasound
Record updated
23 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adults aged ≥18 years
  • Receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA)
  • Scheduled for elective surgery under general anesthesia
  • Able to provide written informed consent

Who cannot take part

  • Prior gastric or esophageal surgery
  • Emergency surgery
  • Severe gastroesophageal reflux disease
  • Known gastroparesis
  • Pregnancy
  • Inability to provide informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can delay gastric emptying and may increase residual gastric contents before general anesthesia. Current perioperative recommendations for withholding GLP-1 RAs (e.g., a fixed 7-day discontinuation for weekly agents) are largely consensus-based, and it is unclear whether gastric emptying normalizes abruptly after a single threshold interval. This prospective observational cohort study will evaluate how preoperative residual gastric content changes with increasing time since the last GLP-1 RA dose, using point-of-care gastric ultrasound performed immediately before induction of anesthesia. Time since last dose will be analyzed as a continuous exposure and across prespecified intervals (≤3 days, 4-7 days, ≥8 days). The primary outcome is ultrasound-estimated gastric volume normalized to body weight (mL/kg), derived from antral cross-sectional area. Secondary outcomes include the presence of a "high-risk stomach" based on gastric volume criteria and qualitative ultrasound findings. The study will also assess whether body mass index modifies the relationship between cessation interval and gastric volume, thereby supporting individualized perioperative risk assessment.

The 3 groups in the trial

  • GLP-1 RA cessation ≤3 days

    Participants using GLP-1 receptor agonists whose last dose was taken ≤3 days before the preoperative gastric ultrasound assessment (performed immediately prior to induction of anesthesia).

    Treatment: Preoperative gastric ultrasound

  • GLP-1 RA cessation 4-7 days

    Participants using GLP-1 receptor agonists whose last dose was taken 4-7 days before the preoperative gastric ultrasound assessment (performed immediately prior to induction of anesthesia).

    Treatment: Preoperative gastric ultrasound

  • GLP-1 RA cessation ≥8 days

    Participants using GLP-1 receptor agonists whose last dose was taken ≥8 days before the preoperative gastric ultrasound assessment (performed immediately prior to induction of anesthesia).

    Treatment: Preoperative gastric ultrasound

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Time-dependent Recovery of Gastric Emptying After Cessation of Glucagon-like Peptide-1 Receptor Agonists: a Prospective Observational Gastric Ultrasound Study
Record updated
23 January 2026